Eris Lifesciences Ltd
NSE:ERIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eris Lifesciences Ltd
NSE:ERIS
|
IN |
|
Lumentum Holdings Inc
NASDAQ:LITE
|
US |
|
Vedanta Ltd
NSE:VEDL
|
IN |
|
Parkmead Group PLC
LSE:PMG
|
UK |
|
Wewards Inc
OTC:WEWA
|
US |
|
M
|
Mondi PLC
F:KYC
|
UK |
Wall St Price Targets
ERIS Price Targets Summary
Eris Lifesciences Ltd
According to Wall Street analysts, the average 1-year price target for ERIS is 1 742.98 INR with a low forecast of 1 449.35 INR and a high forecast of 2 037 INR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ERIS's stock price target?
Price Target
1 742.98
INR
According to Wall Street analysts, the average 1-year price target for ERIS is 1 742.98 INR with a low forecast of 1 449.35 INR and a high forecast of 2 037 INR.
What is the Revenue forecast for Eris Lifesciences Ltd?
Projected CAGR
13%
Over the last 12 years, the compound annual growth rate for Revenue has been 18%. The projected CAGR for the next 4 years is 13%.
What is the Gross Profit forecast for Eris Lifesciences Ltd?
Projected CAGR
13%
Over the last 12 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 4 years is 13%.
What is the Operating Income forecast for Eris Lifesciences Ltd?
Projected CAGR
19%
Over the last 12 years, the compound annual growth rate for Operating Income has been 20%. The projected CAGR for the next 4 years is 19%.
What is the Pre-Tax Income forecast for Eris Lifesciences Ltd?
Projected CAGR
34%
Over the last 12 years, the compound annual growth rate for Pre-Tax Income has been 16%. The projected CAGR for the next 3 years is 34%.
What is the Net Income forecast for Eris Lifesciences Ltd?
Projected CAGR
30%
Over the last 12 years, the compound annual growth rate for Net Income has been 16%. The projected CAGR for the next 4 years is 30%.
